Bosulif® (bosutinib) – Expanded indication, new formulation approval
September 26, 2023 - The FDA approved Pfizer’s Bosulif (bosutinib), for treatment of adult and pediatric patients 1 year of age and older with chronic phase (CP) Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+ CML), newly-diagnosed or resistant or intolerant to prior therapy.
Top